Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00255567
Recruitment Status : Completed
First Posted : November 21, 2005
Last Update Posted : March 22, 2016
Information provided by (Responsible Party):
Drugs for Neglected Diseases

November 16, 2005
November 21, 2005
March 22, 2016
November 2004
January 2010   (Final data collection date for primary outcome measure)
parasitological clearance at 6 months post treatment by splenic, lymph node, or bone marrow smear. [ Time Frame: 6 months post treatment ]
Not Provided
Complete list of historical versions of study NCT00255567 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan
The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.

Currently in the three countries, Sudan, Kenya and Ethiopia many of the patients present themselves in remote areas and need to be treated in relative resource poor settings. It is for this reason that standardised treatment with proven efficacy is much needed. A shorter course of treatment is not only advantageous for the patient but also reduces the overall case load in the clinics thus reducing the risk of disease outbreaks in already immuno-compromised kala-azar patients. Paromomycin, either alone or in combination with SSG would decrease the treatment duration substantially. An additional added value of combination therapy is that it is likely to reduce the chances of development of parasite resistance against the individual drugs.

Leishmaniasis experts in the three countries are in agreement that there are potential benefits of the combination treatment of SSG and PM and that its efficacy should be evaluated with the view to introduce this protocol if proven efficacious and safe. There is ample circumstantial evidence of the use of this combination therapy and its efficacy and tolerability as a standardized protocol. This can only be confirmed through a randomised controlled study with 6 months follow up.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Visceral Leishmaniasis
  • Drug: Sodium Stibogluconate
    Sodium Stibogluconate 20mg/kg/day for 30 days
  • Drug: Paromomycin sulphate
    Paromomycin sulphate
  • Drug: SSG and Paromomycin sulphate
    SSG and Paromomycin Sulphate 17 days
  • Active Comparator: 1
    Sodium Stibogluconate (30 days)
    Intervention: Drug: Sodium Stibogluconate
  • Experimental: 2
    Paromomycin Sulphate (21 days)
    Intervention: Drug: Paromomycin sulphate
  • Experimental: 3
    Sodium Stibogluconate + Paromomycin Sulphate (17 days)
    Intervention: Drug: SSG and Paromomycin sulphate

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
January 2010
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients for whom written informed consent has been signed by the patients themselves (if aged 18 years and over) or by parents(s) or legal guardian for patients under 18 years of age.
  2. Patients aged between 4 and 60 years (inclusive) who are able to comply with the protocol. It is justified to include children because they represent more than 50% of VL cases.
  3. Patients with clinical signs and symptoms of VL and diagnosis confirmed by visualization of parasites in tissue samples (spleen, lymph node or bone marrow) on microscopy.

Exclusion Criteria:

  1. Patients who have received any anti-leishmanial drug in the last 6 months.
  2. Patients with a negative splenic / lymph node / bone marrow smears.
  3. Patients with a clinical contraindication to splenic/lymph node/ bone marrow aspirates.
  4. Patients with severe protein and or caloric malnutrition (Kwashiokor or marasmus)
  5. Patients with previous hypersensitivity reaction to SSG or aminoglycosides.
  6. Patients suffering from a concomitant severe infection such as TB or any other serious underlying disease (cardiac, renal, hepatic) which would preclude evaluation of the patients response to study medication.
  7. Patients suffering from other conditions associated with splenomegaly such as schistosomiasis.
  8. Patients with previous history of cardiac arrhythmia or an abnormal ECG
  9. Patients who are pregnant or lactating.
  10. Patients with haemoglobin < 5gm/dl.
  11. Patients with WBC < 1 x 10³/mm³.
  12. Patients with platelets < 40,000/mm³.
  13. Patients with liver function tests more than three times the normal range
  14. Patients with serum creatinine outside the normal range for age and gender
  15. Patients with pre-existing clinical hearing loss.
Sexes Eligible for Study: All
4 Years to 60 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Ethiopia,   Kenya,   Sudan,   Uganda
Not Provided
Not Provided
Drugs for Neglected Diseases
Drugs for Neglected Diseases
Not Provided
Study Director: Manica Balasegaram Drugs for Neglected Diseases
Drugs for Neglected Diseases
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP